Vraylar (cariprazine) is a brand-name oral capsule taken once daily to help treat mental health conditions such as depression, schizophrenia, and bipolar disorder. You can take Vraylar in the morning ...

Vraylar (cariprazine) is a prescription drug used to treat certain mental health conditions, such as depression and bipolar I disorder. Vraylar comes as a capsule that you swallow once daily.

The approval of medicines called second-generation antipsychotics has allowed bipolar I and other associated conditions to be treated. A person with bipolar I disorder can go through various mood ...

AbbVie has secured its fourth FDA approval for Vraylar, adding adjunctive therapy of major depressive disorder (MDD) to a list that includes schizophrenia and manic and depressive episodes in bipolar ...

A patient with depression says she was "stuck" until AbbVie's Vraylar gave her "a lift," which is the theme of the company's latest ad campaign for the mental health drug. Vraylar, a sales blockbuster ...

Vraylar may lead to mild side effects such as movement issues, restlessness, sleepiness, and weight gain, which are often temporary. Serious side effects may occur, including neuroleptic malignant ...

Vraylar (cariprazine) is an atypical antipsychotic prescribed for schizophrenia, bipolar mania, bipolar depression, or as an add-on treatment for major depressive disorder in adults. It’s also ...

The U.S. Food and Drug Administration today approved Vraylar (cariprazine) capsules to treat schizophrenia and bipolar disorder in adults. "Schizophrenia and bipolar disorder can be disabling and can ...

The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...

This listing is a new step towards more equitable access to mental illness medication in Canada. As up to 90% of Canadians with serious mental illness are unemployed 3, public plan coverage is ...

There will be DTCs, “strong positioning and multiple indications” for AbbVie's new drug as it looks to shore up the “share of voice” for the new drug. (AbbVie) AbbVie’s new $8.7 billion buyout of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...